Drug – bio-affecting and body treating compositions – Identification or warning feature – Taste or smell or chemical irritation to the eye – nose – or...
Patent
1989-10-10
1991-07-30
Raymond, Richard L.
Drug, bio-affecting and body treating compositions
Identification or warning feature
Taste or smell or chemical irritation to the eye, nose, or...
5142318, 5142375, 514252, 514255, 514256, 514332, 514357, 514374, 514378, 514385, 514422, 514423, 514476, 514483, 514823, 514885, A61K 4900, A61K 31535, A61K 31495, A61K 31505
Patent
active
050358782
ABSTRACT:
Various types of biological treatments, including antineoplastic treatments with antineoplastic drugs, can result in damage to the blood-forming function of the bone marrow. This damage can be reversed, at least to some degree, with an effective amount (preferably an extremely low dose) of a pharmaceutically acceptable dithiocarbamic compound, including a compound of the formula R.sub.1 R.sub.2 NCSSM or R.sub.1 R.sub.2 NCSS-SCSNR.sup.3 R.sup.4, wherein R.sup.1, R.sup.2, R.sup.3, and R.sup.4 are the same or different aliphatic or cycloaliphatic or heterocycloaliphatic groups, unsubstituted or substituted by hydroxyl, or one of R.sup.1 and R.sup.2 and one of R.sup.3 and R.sup.4 can be H, or R.sup.1 and R.sup.2 or R.sup.3 and R.sup.4, taken together with the N atom upon which the pair of R groups is substituted, can be a 5- or 6-member N-heterocyclic ring which is aliphatic or aliphatic interrupted by a ring oxygen or second ring nitrogen, and M is H or one equivalent of a pharmaceutically acceptable cation, in which case the rest of the molecule is negatively charged. The dosage in mammals can range from about 0.001 to 30 mg/kg of body weight. For larger mammals, including humans, a typical dosage unit is less than 10 mg/kg, e.g. <3 mg/kg. The dosage unit can be dissolved in a suitable pharmaceutically acceptable carrier (e.g. an aqueous medium) and is then preferably administered intravenously within 8 hours of the administration of the agent which can cause bone marrow damage. The extremely low dosages particularly preferred in this invention do not cause any significant side effects.
REFERENCES:
patent: 4148885 (1979-04-01), Renoux et al.
patent: 4426372 (1984-01-01), Borch
patent: 4581224 (1986-04-01), Borch
patent: 4594238 (1986-06-01), Borch
patent: 4645661 (1987-02-01), Schonbaum
Prasad, H. et al., Induction of Micronuclei in Bone Marrow Cells of Mice by Tetramethyl Thurum Disulfide Cell and Chromosome Res. 6(3); 82-4 (1983).
Gamelli, R. L. et al., The Effect of Disulfiram on Cyclophosphamide-Mediated Myeloid Toxicity Cancer Chemother. Pharmacol., 16: 153-5 (1986).
Sunderman, F. W. Sr., The Treatment of Acute Nickel Carbonyl Poisoning with Sodium Diethyldithlocarbamate, Annals Clinical Res. 3: 182-5 (1971).
J. R. M. Innes et al., J. National Cancer Instit., 42, 1101 (1969).
D. A. Juckett et al., AACR Abstracts, No. 1274 (1984).
D. L. Bodenner et al., Cancer Res., 46, 2751 (1986).
M. M. Jones et al., Cancer Chemother. Pharmacol., 17, 38 (1986).
R. G. Evans et al., Cancer Res., 44, 3686 (1984).
J. D. Khandekar, Res. Commun. Chem. Path. Pharmacol., 40, 55 (1983).
A. Gringeri and R. F. Borch, AACR Abstracts, No. 1471 (1984).
I. M. Pannacciulli et al., Br. J. Cancer, 59, 371 (1989).
Borch Richard F.
Schmalbach Therese K.
Hollinden Gary E.
Raymond Richard L.
University of Rochester
LandOfFree
Use of dithiocarbamates to counteract myelosuppression does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of dithiocarbamates to counteract myelosuppression, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of dithiocarbamates to counteract myelosuppression will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1541680